Methods for Inhibiting the Progression of Neurodegenerative Diseases
AssigneeRetrotope, Inc.
InventorsPeter Milner, Mikhail Sergeevich Shchepinov
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising deuterated arachidonic acid or an ester thereof.
Claims23
A method for reducing neurodegenerative disease progression in a patient, the method comprising:
- administering an effective amount of a deuterated arachidonic acid, an ester thereof, or a prodrug thereof, to reduce said disease progression in said patient;
- wherein a therapeutic concentration of deuterated arachidonic acid in the motor neurons is sufficient to reduce disease progression, wherein said reduction is measured to be at least about 30% reduction relative to the rate of disease progression during the natural history of the patient.
A method for reducing disease progression of a neurodegenerative disease treatable with 7,7,10,10,13,13-D6-arachidonic acid or an ester thereof in an adult patient, the method comprising:
- administering 7,7,10,10,13,13-D6-arachidonic acid or ester thereof to the patient with a dosing regimen that comprises a primer or loading dose and a maintenance dose thereby reducing said disease progression in said patient, wherein:
- a) said primer or loading dose comprises periodic administration of from about 0.5 grams to about 5 grams of 7,7,10,10,13,13-D6-arachidonic acid or ester thereof per day, wherein said primer dose is continued for about 24 days to about 45 days;
- and
- b) subsequent to the completion of the primer or loading dose, administering said maintenance dose of about 30% to about 70% of the primer or loading dose of 7,7,10,10,13,13-D6-arachidonic acid or ester thereof per day thereof such that the rate of disease progression is reduced,
- wherein the neurodegenerative disease is mediated at least in part by lipid peroxidation of polyunsaturated fatty acids in neurons of the patient.
A kit of parts comprising a set of capsules each comprising a partial loading dose of deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete loading dose per day.
A kit of parts comprising a set of capsules each comprising a partial loading dose of deuterated arachidonic acid or an ester thereof, such that nine of said capsules comprise a complete loading dose per day.
A kit of parts comprising a set of capsules each comprising a partial maintenance dose of deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete maintenance dose per day.
A kit of parts comprising a set of capsules each comprising a partial maintenance dose of deuterated arachidonic acid or an ester thereof, such that five of said capsules comprise a complete maintenance dose per day.
Dependencies are inferred from the claim text.